Clinical trial
A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus
NCT04598893 is registered in ClinicalTrials.gov with Provention Bio, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus
- Lead sponsor
- Provention Bio, a Sanofi Company
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- October 26, 2020
- Completion date
- November 30, 2026
- Enrollment
- 188 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.